Jubilant life AR:
#Pharmaceuticals segment, which reported EBITDA of ` 15,555 million, a growth of 13% YoY with a margin of 27.2%. The Pharmaceuticals segment accounted for 78% of the overall EBITDA for the Company during the year.
#Life Science Ingredients reported EBITDA of ` 4,310 million translating to EBITDA margin of 13.6%.
#Discovery & Development Solutions segment EBITDA was at ` 734 million translating to EBITDA margin of 28.1%.
#We are the third largest player in the nuclear medicine industry and the leading player in the US based on market share of certain products, namely, MAA and DTPA.
#We believe we are well-positioned in the high-value niche business of Radiopharmaceuticals, offering quality diagnostic imaging and therapeutic radiopharmaceutical products. We specialise in lung, thyroid, bone and cardiac imaging products as well as thyroid disease therapy
#For diagnostics, our key products include MAA and DTPA, for both of which we have leadership position in the US. For therapeutics, our key products include Iodine-131 (‘I-131’), of which we are one of only three US FDA approved manufacturers globally.
#We are the second largest centralised commercial radiopharmacy network partner in the United States with over 50 radiopharmacies across 22 states.
#We are the second largest player in the allergenic extract market in the United States and are currently the sole producer and supplier of venom products for the treatment of allergies in the United States.
#Contract Manufacturing of Sterile Injectables and Non-Sterile Produc: We serve seven of the top 20 pharmaceutical companies globally.
#Active Pharmaceutical Ingredients (APIs ): We develop and produce APIs in the therapeutic areas of the Cardiovascular System (CVS), Central Nervous System (CNS), Gastrointestinal (GI), Anti-infectives and Anti-depressants. We have forward integration with our Solid Dosage Formulations business line.
#Solid Dosage Formulation : We believe we have a strong product portfolio and are currently leaders in the US for Prochlorperazine, Methylprednisolone and Terazosin and we rank among the top three in the US for a few other products. We focus primarily on the manufacture and sale of solid dosage formulations for Cardiovascular System (CVS), Central Nervous System (CNS), Gastrointestinal (GI) and Anti-allergy therapeutic categories.
#Over 70% of our assets are based in North America. This includes our four manufacturing facilities (CMO Spokane facility, CMO Montreal facility, radiopharmaceuticals Montreal facility and Solid Dosage Formulations Salisbury facility), our network of over 50 Radiopharmacies in North America and our highly differentiated Allergy Therapy Products business backed by one of the oldest and most trusted brands in the US.
#Diverse sources of revenue with a de-risked business model: : As on 31st March, 2020, we had a diversified product portfolio including diagnostic and therapeutic radiopharmaceuticals, a broad range of sterile injectables and non-sterile products, over 200 different allergens and standard allergy vaccine mixtures, 56 commercialised generic solid dosage formulations and 44 commercialised APIs sold across markets globally. As a result of our diversified product portfolio, we benefit from diversified revenues between three differentiated businesses.
#top 10 customers (excluding GPOs but including customers purchasing goods and services through such GPOs) contributing 31% to the total Pharma revenues as on 31st March, 2020.
Strong product pipeline : Our Radiopharmaceuticals business line is in the process of developing certain products such as I-131 meta-Iodobenzylguanidine (‘mIBG’) for which we plan to make a New Drug Application (‘NDA’) filing.
In addition, we have seven other products in different stages of development for which we may consider making 505(b) (2) filings.
USFDA Inspection: The Nanjangud plant was a coinspection by US FDA and Health Canada. During this financial year, Health Canada removed the OAI classification for the Nanjangud plant and we expect favourable resolution from the US FDA as well. Regarding the Roorkee facility, we have submitted comprehensive responses to the US FDA and have completed remediation activities by consulting with third party consultants and are hopeful of clearance from US FDA once they re-inspect the plant.
Life Science Ingredients (LSI): The Company is a global leader in Pyridine and its derivatives (Speciality Ingredients), Vitamin B3, Acetic Anhydride and Ethyl Acetate.
We are the world’s largest producer of Bio-based Acetaldehyde.
Nutritional Produc: One of our key products in this segment is Vitamin B3 (Niacinamide and Niacin) for which we hold a global leadership position. Our Vitamin B3 is fully backward integrated with feedstock raw material (i.e. Beta Picoline and 3-Cyanopyridine) which is produced by our Specialty Intermediates business as a by-product.
#We are the market leader in India and globally #4 in Acetic Anhydride merchant market.
#we have become one of the largest Ethanol supplier to Oil Marketing Companies (OMCs) among standalone distilleries. Moreover, a price increase based on Government’s new policy has improved our business margins.
Disc.:Invested.